Toxicities and pharmacokinetics of subconjunctival injection of liposomal amphotericin B

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 4, 2009, Pages 549-553

  Kaji, Yuichi ^a   Yamamoto, Erika ^a   Hiraoka, Takahiro ^a   Oshika, Tetsuro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Amphotericin B deoxycholate; Deoxycholate; Liposomal amphotericin B; Ocular toxicity; Pharmacokinetics; Subconjunctival injection

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DEOXYCHOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMICROSCOPY; CELL INFILTRATION; CHEMOSIS; CONTROLLED STUDY; CORNEA EDEMA; CORNEA EPITHELIUM; CORNEA NECROSIS; DOSE TIME EFFECT RELATION; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG TISSUE LEVEL; EXPERIMENTAL RABBIT; EYE TOXICITY; HISTOPATHOLOGY; INFLAMMATORY CELL; INJECTION SITE INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; SLIT LAMP; TOXICITY TESTING;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CONJUNCTIVA; CONJUNCTIVAL DISEASES; CORNEAL DISEASES; CORNEAL STROMA; INJECTIONS; MALE; RABBITS;

EID: 62149119933     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-1003-4     Document Type: Article

References (12)

1. Shukla PK, Kumar M, Keshava GB (2008) Mycotic keratitis: An overview of diagnosis and therapy. Mycoses 51:183-199, doi: 10.1111/ j.1439-0507.2007.01480.x
2. Thomas PA (1994) Mycotic keratitis-an underestimated mycosis. J Med Vet Mycol 32:235-256, doi: 10.1080/02681219480000321
3. Johns KJ, O'Day DM (1988) Pharmacologic management of keratomycoses. Surv Ophthalmol 33:178-188, doi: 10.1016/0039-6257(88)90086-0
4. Ellison AC, Newmark E, Kaufman HE (1969) Chemotherapy of experimental keratomycosis. Am J Ophthalmol 68:812-819
5. Janknegt R, de Marie S, Bakker-Woudenberg IA, Crommelin DJ (1992) Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet 23:279-291
6. Veerareddy PR, Vobalaboina V (2004) Lipid-based formulations of amphotericin B. Drugs Today (Barc) 40:133-145, doi: 10.1358/ dot.2004.40.2.799425
7. de Marie S, Janknegt R, Bakker-Woudenberg IA (1994) Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 33:907-916, doi: 10.1093/jac/33.5.907
8. Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S (2004) Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model. Ophthalmic Res 36:172-176, doi: 10.1159/000077331
9. Williams TE, O'Day DM, Head WS, Robinson RD (1990) Measurements of antifungal levels in corneal tissue: A simplified bioassay for amphotericin B. Graefes Arch Clin Exp Ophthalmol 228:538-540, doi: 10.1007/BF00918487
10. O'Day DM, Smith R, Stevens JB, Williams TE, Robinson RD, Head WS (1991) Toxicity and pharmacokinetics of subconjunctival amphotericin B. An experimental study. Cornea 10:411-417, doi: 10.1097/ 00003226-199109000-00010
11. Adler-Moore J, Proffitt RT (2002) AmBisome: Liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 49(Suppl 1):21-30
12. Adler-Moore J (1994) AmBisome targeting to fungal infections. Bone Marrow Transplant 14(Suppl 5):S3-S7